Golden State Equity Partners Aerovate Therapeutics, Inc. Transaction History
Golden State Equity Partners
- $402 Million
- Q4 2023
A detailed history of Golden State Equity Partners transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Golden State Equity Partners holds 10,880 shares of AVTE stock, worth $19,584. This represents 0.06% of its overall portfolio holdings.
Number of Shares
10,880
Previous 10,530
3.32%
Holding current value
$19,584
Previous $142,000
73.24%
% of portfolio
0.06%
Previous 0.04%
Shares
5 transactions
Others Institutions Holding AVTE
# of Institutions
83Shares Held
20.5MCall Options Held
0Put Options Held
0-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$6.77 Million6.47% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.2MShares$3.96 Million6.85% of portfolio
-
Atlas Venture Life Science Advisors, LLC2.04MShares$3.67 Million7.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.68MShares$3.02 Million0.63% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.2MShares$2.17 Million1.87% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $44M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...